ArticlePloS one2026
Feasibility of establishing a serosurveillance system using residual specimens from district-level hospitals: A case study in Choma and Ndola Districts of Zambia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual blood specimens collected at health care facilities provide a low-cost and readily available specimen source to monitor population immunity through serological surveillance compared to more resource-intensive probability-based surveys. Despite concerns about the representativeness of these specimens, there has recently been increased interest in the use of residual specimens, driven by the need for rapid estimates of seroprevalence during outbreaks to inform response and prevention. Although residual specimen collection is a key component of surveillance systems in some settings, there is limited evidence of its implementation in low- and middle-income countries. We conducted a pilot project at three health facilities in two districts in Zambia between September 2021 through July 2022 to demonstrate the feasibility of residual blood specimen collection integrated into the health system to estimate measles seroprevalence. Through this pilot project, we were able to collect residual pediatric and adult specimens but with some modifications needed if residual specimen collection were to be implemented at scale, such as better integration into the routine functioning of laboratories and health facilities. This paper summarizes our experiences designing and implementing this residual blood specimen collection, including the lessons learned and recommendations for collecting residual specimens from hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.